26 results on '"Azimi, Parvin"'
Search Results
2. Congenital Malaria Due to Plasmodium falciparum.
- Author
-
Hindi, Robert D. and Azimi, Parvin H.
- Subjects
- *
PLASMODIUM falciparum ,MALARIA transmission - Abstract
Abstract. Malaria manifested during the first few months of life may be the result of acquisition during pregnancy, at the time of delivery, or by mosquito bite after birth. Both congenital and perinatal malaria are acquired by the transmission of parasitized maternal erythrocytes across the placenta. An infant is described whose mother was diagnosed to have malaria at six months of gestation. The infant developed intermittent fever at 5 weeks of age and presented with anemia and hepatosplenomegaly at 3 months of age at which time Plasmodium falciparum parasites were found on examination of thick smears of the infant's blood. IgG and IgM antimalarial antibodies were detected in maternal blood, but only IgG antibodies were found in the infant's blood at delivery and at the time of diagnosis. These transplacentally transmitted antibodies may afford transient protection for the infant and thus delay the onset of clinical manifestations. Due to the absence of an exoerythrocytic life cycle in congenitally acquired malaria, chloroquine is the drug of choice for treatment. Infections with chloroquine-resistant strains require multiple drug therapy. Pediatrics 66:977-979, 1980; congenital malaria, chloroquine, malaria, Plasmodium falciparum, hepatosplenomegaly. [ABSTRACT FROM AUTHOR]
- Published
- 1980
- Full Text
- View/download PDF
3. Sustained Within-season Vaccine Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New Vaccine Surveillance Network, 2015–2016 Through 2019–2020.
- Author
-
Sahni, Leila C, Naioti, Eric A, Olson, Samantha M, Campbell, Angela P, Michaels, Marian G, Williams, John V, Staat, Mary Allen, Schlaudecker, Elizabeth P, McNeal, Monica M, Halasa, Natasha B, Stewart, Laura S, Chappell, James D, Englund, Janet A, Klein, Eileen J, Szilagyi, Peter G, Weinberg, Geoffrey A, Harrison, Christopher J, Selvarangan, Rangaraj, Schuster, Jennifer E, and Azimi, Parvin H
- Subjects
- *
INFLUENZA prevention , *INFLUENZA vaccines , *RESPIRATORY diseases , *CONFIDENCE intervals , *CHILDREN'S hospitals , *MULTIPLE regression analysis , *ACQUISITION of data , *VACCINE effectiveness , *AGE factors in disease , *MEDICAL records , *DESCRIPTIVE statistics , *RESEARCH funding , *ODDS ratio , *HOSPITAL care of children , *LONGITUDINAL method , *EVALUATION , *CHILDREN - Abstract
Background Adult studies have demonstrated within-season declines in influenza vaccine effectiveness (VE); data in children are limited. Methods We conducted a prospective, test-negative study of children 6 months through 17 years hospitalized with acute respiratory illness at 7 pediatric medical centers during the 2015–2016 through 2019–2020 influenza seasons. Case-patients were children with an influenza-positive molecular test matched by illness onset to influenza-negative control-patients. We estimated VE [100% × (1 – odds ratio)] by comparing the odds of receipt of ≥1 dose of influenza vaccine ≥14 days before illness onset among influenza-positive children to influenza-negative children. Changes in VE over time between vaccination date and illness onset date were estimated using multivariable logistic regression. Results Of 8430 children, 4653 (55%) received ≥1 dose of influenza vaccine. On average, 48% were vaccinated through October and 85% through December each season. Influenza vaccine receipt was lower in case-patients than control-patients (39% vs 57%, P <.001); overall VE against hospitalization was 53% (95% confidence interval [CI]: 46, 60%). Pooling data across 5 seasons, the odds of influenza-associated hospitalization increased 4.2% (−3.2%, 12.2%) per month since vaccination, with an average VE decrease of 1.9% per month (n = 4000, P =.275). Odds of hospitalization increased 2.9% (95% CI: −5.4%, 11.8%) and 9.6% (95% CI: −7.0%, 29.1%) per month in children ≤8 years (n = 3084) and 9–17 years (n = 916), respectively. These findings were not statistically significant. Conclusions We observed minimal, not statistically significant within-season declines in VE. Vaccination following current Advisory Committee on Immunization Practices (ACIP) guidelines for timing of vaccine receipt remains the best strategy for preventing influenza-associated hospitalizations in children. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.
- Author
-
Payne, Daniel C., Selvarangan, Rangaraj, Azimi, Parvin H., Boom, Julie A., Englund, Janet A., Staat, Mary Allen, Halasa, Natasha B., Weinberg, Geoffrey A., Szilagyi, Peter G., Chappell, James, McNeal, Monica, Klein, Eileen J., Sahni, Leila C., Johnston, Samantha H., Harrison, Christopher J., Baker, Carol J., Bernstein, David I., Moffatt, Mary E., Tate, Jacqueline E., and Mijatovic-Rustempasic, Slavica
- Subjects
- *
ROTAVIRUS vaccines , *DRUG efficacy , *VACCINATION of children , *PUBLIC health , *HOSPITAL care - Abstract
Background. Using a multicenter, active surveillance network from 2 rotavirus seasons (2012 and 2013), we assessed the vaccine effectiveness of RV5 (RotaTeq) and RV1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency department (ED) visits for numerous demographic and secular strata. Methods. We enrolled children hospitalized or visiting the ED with acute gastroenteritis (AGE) for the 2012 and 2013 seasons at 7 medical institutions. Stool specimens were tested for rotavirus by enzyme immunoassay and genotyped, and rotavirus vaccination histories were compared for rotavirus-positive cases and rotavirus-negative AGE controls. We calculated the vaccine effectiveness (VE) for preventing rotavirus associated hospitalizations and ED visits for each vaccine, stratified by vaccine dose, season, clinical setting, age, predominant genotype, and ethnicity. Results. RV5-specific VE analyses included 2961 subjects, 402 rotavirus cases (14%) and 2559 rotavirus-negative AGE controls. RV1-specific VE analyses included 904 subjects, 100 rotavirus cases (11%), and 804 rotavirus-negative AGE controls. Over the 2 rotavirus seasons, the VE for a complete 3-dose vaccination with RV5 was 80% (confidence interval [CI], 74%-84%), and VE for a complete 2-dose vaccination with RV1 was 80% (CI, 68%-88%). Statistically significant VE was observed for each year of life for which sufficient data allowed analysis (7 years for RV5 and 3 years for RV1). Both vaccines provided statistically significant genotype-specific protection against predominant circulating rotavirus strains. Conclusions. In this large, geographically and demographically diverse sample of US children, we observed that RV5 and RV1 rotavirus vaccines each provided a lasting and broadly heterologous protection against rotavirus gastroenteritis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015–2016.
- Author
-
Hamdan, Lubna, Probst, Varvara, Haddadin, Zaid, Rahman, Herdi, Spieker, Andrew J., Vandekar, Simon, Stewart, Laura S., Williams, John V., Boom, Julie A., Munoz, Flor, Englund, Janet A., Selvarangan, Rangaraj, Staat, Mary A., Weinberg, Geoffrey A., Azimi, Parvin H., Klein, Eileen J., McNeal, Monica, Sahni, Leila C., Singer, Monica N., and Szilagyi, Peter G.
- Subjects
- *
HOSPITAL care of children , *INFLUENZA , *ACUTE diseases , *PANDEMICS , *NEUROMUSCULAR diseases , *NUCLEIC acid amplification techniques , *OSELTAMIVIR - Abstract
Background: Antiviral treatment is recommended for all hospitalized children with suspected or confirmed influenza, regardless of their risk profile. Few data exist on adherence to these recommendations, so we sought to determine factors associated with influenza testing and antiviral treatment in children. Methods: Hospitalized children <18 years of age with acute respiratory illness (ARI) were enrolled through active surveillance at pediatric medical centers in seven cities between 11/1/2015 and 6/30/2016; clinical information was obtained from parent interview and chart review. We used generalized linear mixed‐effects models to identify factors associated with influenza testing and antiviral treatment. Results: Of the 2299 hospitalized children with ARI enrolled during one influenza season, 51% (n = 1183) were tested clinically for influenza. Clinicians provided antiviral treatment for 61 of 117 (52%) patients with a positive influenza test versus 66 of 1066 (6%) with a negative or unknown test result. In multivariable analyses, factors associated with testing included neuromuscular disease (aOR = 5.35, 95% CI [3.58–8.01]), immunocompromised status (aOR = 2.88, 95% CI [1.66–5.01]), age (aOR = 0.93, 95% CI [0.91–0.96]), private only versus public only insurance (aOR = 0.78, 95% CI [0.63–0.98]), and chronic lung disease (aOR = 0.64, 95% CI [0.51–0.81]). Factors associated with antiviral treatment included neuromuscular disease (aOR = 1.86, 95% CI [1.04, 3.31]), immunocompromised state (aOR = 2.63, 95% CI [1.38, 4.99]), duration of illness (aOR = 0.92, 95% CI [0.84, 0.99]), and chronic lung disease (aOR = 0.60, 95% CI [0.38, 0.95]). Conclusion: Approximately half of children hospitalized with influenza during the 2015–2016 influenza season were treated with antivirals. Because antiviral treatment for influenza is associated with better health outcomes, further studies of subsequent seasons would help evaluate current use of antivirals among children and better understand barriers for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018.
- Author
-
Tenforde, Mark W, Campbell, Angela P, Michaels, Marian G, Harrison, Christopher J, Klein, Eileen J, Englund, Janet A, Selvarangan, Rangaraj, Halasa, Natasha B, Stewart, Laura S, Weinberg, Geoffrey A, Williams, John V, Szilagyi, Peter G, Staat, Mary A, Boom, Julie A, Sahni, Leila C, Singer, Monica N, Azimi, Parvin H, Zimmerman, Richard K, McNeal, Monica M, and Talbot, H Keipp
- Subjects
- *
INFLUENZA diagnosis , *REVERSE transcriptase polymerase chain reaction , *RESPIRATORY disease diagnosis , *RESPIRATORY infections , *POLYMERASE chain reaction , *HOSPITAL care of children - Abstract
At nine US hospitals that enrolled children hospitalized with acute respiratory illness (ARI) during 2015-2016 through 2017-2018 influenza seasons, 50% of children with ARI received clinician-initiated testing for influenza and 35% of cases went undiagnosed due to lack of clinician-initiated testing. Marked heterogeneity in testing practice was observed across sites. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods.
- Author
-
Matson, David O, Staat, Mary Allen, Azimi, Parvin, Itzler, Robbin, Bernstein, David I, Ward, Richard L, Dahiya, Ram, DiNubile, Mark J, Barnes-Eley, Myra, and Berke, Tamas
- Subjects
- *
ROTAVIRUS diseases , *HOSPITAL care of children , *CHILDREN'S hospitals , *HOSPITALS - Abstract
Aim: The number of rotavirus hospitalisations is usually estimated from assigned diagnosis codes for gastroenteritis despite lack of validation for these indirect methods. Reliable estimates before and after introduction of vaccines are needed to quantify the absolute impact of new immunisation programs. Methods: This 2-year study conducted at three hospitals prior to the licensure of the rotavirus vaccines in the USA compared two indirect methods for estimating hospitalisations for rotavirus gastroenteritis with estimates derived from prospective recruitment of children presenting with diarrhoea, vomiting or fever. For active surveillance, rotavirus gastroenteritis was confirmed by demonstration of stool antigen. The indirect residual and proportional methods assumed rotavirus to have caused a proportion of hospitalisations coded as acute gastroenteritis identified from computerised records. Results: There were 447 rotavirus hospitalisations among inpatients 31 days through 4 years of age admitted with vomiting and/or diarrhoea, compared with 306 and 228 hospitalisations identified by the two indirect methods. Only 52% of children hospitalised with gastroenteritis received a qualifying diagnosis code at discharge. Relative to active surveillance, the sensitivity and specificity (95% confidence interval (CI)) in identifying rotavirus-attributable hospitalisations was 45% (95% CI: 43-48%) and 89% (88-90%) for the residual method and 34% (30-39%) and 92% (90-94%) for the proportional method. Conclusions: Many children admitted to the hospital with diarrhoea, vomiting or fever were not assigned discharge codes for acute gastroenteritis. Consequently, standard indirect methods missed a substantial number of rotavirus-associated hospitalisations, thereby underestimating the absolute number of children who could potentially benefit from vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Burden of Rotavirus Disease Among Children Visiting Pediatric Emergency Departments in Cincinnati, Ohio, and Oakland, California, in 1999-2000.
- Author
-
Yee, Eileen L., Staat, Mary Allen, Azimi, Parvin, Bernstein, David I., Ward, Richard L., Schubert, Charles, Matson, David O., Turcios-Ruiz, Reina M., Parashar, Umesh, Widdowson, Marc-Alain, and Glass, Roger I.
- Subjects
- *
ROTAVIRUSES , *GASTROENTERITIS , *JUVENILE diseases , *PEDIATRICS - Abstract
OBJECTIVE. We assessed the incidence of rotavirus disease requiring an emergency department visit among children <5 years of age. METHODS. We conducted active surveillance for acute gastroenteritis in pediatric emergency departments in Cincinnati, Ohio, and Oakland, California, from March 1999 to May 2000, among children 2 weeks to 59 months of age with acute diarrhea and/or vomiting. We obtained clinical and demographic information from participants and tested their stool specimens for rotavirus. RESULTS. Approximately 9% of all emergency department visits at the study sites were attributable to acute gastroenteritis. A total of 1433 children were eligible at the 2 sites; 85% were enrolled and 68% provided a stool specimen. Overall, rotavirus was detected in specimens from 27% of children (30% in Cincinnati and 24% in Oakland). Rotavirus detection was higher in bulk stools, compared with rectal swabs, at both Cincinnati (37% vs 23%) and Oakland (46% vs 18%). Patients with rotavirus had more-severe disease than did those with nonrotavirus gastroenteritis. We estimated that the mean annual incidence of emergency department visits attributable to rotavirus was 12 cases per 1000 children in Cincinnati and 15 cases per 1000 children in Oakland. Through extrapolation, we estimated that rotavirus infection causes ~260 910 emergency department visits per year among US children. CONCLUSION, Active surveillance demonstrated that the burden of laboratory-confirmed rotavirus disease treated in emergency department settings among US children is substantial and greater than estimated previously. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
9. Level of Maternal IgG Anti--Group B Streptococcus Type III Antibody Correlated with Protection of Neonates against Early-Onset Disease Caused by This Pathogen.
- Author
-
Lin, Feng-Ying C., Weisman, Leonard E., Azimi, Parvin H., Philips III, Joseph B., Clark, Penny, Regan, Joan, Rhoads, George G., Frasch, Carl E., Gray, Barry M., Troendle, James, Brenner, Ruth A., Moyer, Patricia, and Clemens, John D.
- Subjects
- *
NEWBORN infant immunology , *MATERNALLY acquired immunity , *STREPTOCOCCUS , *IMMUNOGLOBULINS , *IMMUNE response , *PATHOGENIC microorganisms - Abstract
The present study estimates the level of maternal immunoglobulin (Ig) G anti-group B streptococcus (GBS) type III required to protect neonates against early-onset disease (EOD) caused by this pathogen. Levels of maternal serum IgG anti-GBS type III, measured by enzyme-linked immunosorbent assay, in 26 case patients (neonates with EOD caused by GBS type III) and 143 matched control subjects (neonates colonized by GBS type III who did not develop EOD) of ≥34 weeks gestation were compared. The probability of EOD decreased with increasing levels of maternal IgG anti-GBS type III (P = .01). Neonates whose mothers had ≥10 µg/mL IgG anti-GBS type III had a 91% lower risk for EOD, compared with those whose mothers had levels of <2 µg/mL. A vaccine that induces IgG anti-GBS type III levels of ≥10 µg/mL in mothers can be predicted to offer a significant degree of protection against EOD caused by this pathogen. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
10. Level of Maternal Antibody Required to Protect Neonates against Early-Onset Disease Caused by Group B Streptococcus Type Ia: A Multicenter, Seroepidemiology Study.
- Author
-
Lin, Feng-Ying C., Philips III, Joseph B., Azimi, Parvin H., Weisman, Leonard E., Clark, Penny, Rhoads, George G., Regan, Joan, Concepcion, Nelydia F., Frasch, Carl E., Troendle, James, Brenner, Ruth A., Gray, Barry M., Bhushan, Reva, Fitzgerald, Geri, Moyer, Patricia, and Clemens, John D.
- Subjects
- *
STREPTOCOCCAL diseases , *MATERNALLY acquired immunity , *NEWBORN infant immunology - Abstract
Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccineinduced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born ar ≥34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P = .03). Neonates whose mothers had levels of IgG GBS Ia antibody ≥5 µg/mL had an 88% lower risk (95% confidence interval, 7%–98%) of developing type-specific EOD, compared with those whose mothers had levels <0.5 µg/mL. A vaccine that induces IgG GBS Ia antibody levels ≥5 µg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
11. Rotavirus and Central Nervous System Symptoms: Cause or Contaminant? Case Reports and Review.
- Author
-
Lynch, Maureen, Lee, Brian, Azimi, Parvin, Gentsch, Jon, Glaser, Carol, Gilliam, Sabrina, Chang, Hwa-Gan H., Ward, Richard, and Glass, Roger I.
- Subjects
- *
ROTAVIRUSES , *CENTRAL nervous system diseases - Abstract
Rotavirus is a common cause of severe gastroenteritis in children. In 2 patients with rotavirus gastroenteritis who developed encephalopathy, rotavirus RNA was detected in the cerebrospinal fluid (CSF) by reverse transcription-polymerase chain reaction; in 1 patient, rotavirus RNA was detected on 2 occasions 3 weeks apart. There are increasing reports of cases in which patients who have seizures after an episode of rotavirus diarrhea have evidence of rotavirus in their CSF. A search of 2 large hospital discharge databases suggested that seizures are noted as part of the discharge diagnosis in the records of, at most, <4% of patients with rotavirus diarrhea versus 7% of patients with bacterial diarrhea. Although evidence suggesting that rotavirus is a cause of central nervous system sequelae remains inconclusive, the 2 case reports presented in this study further illustrate a possible association. Further study is required to determine whether detection of rotavirus in CSF represents a true pathogen, CSF contamination that occurs at the time of lumbar puncture or in the laboratory, or carriage of rotavirus RNA in trafficking lymphocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
12. Comparison of Parental Report of Influenza Vaccination to Documented Records in Children Hospitalized With Acute Respiratory Illness, 2015–2016.
- Author
-
Ogokeh, Constance E, Campbell, Angela P, Feldstein, Leora R, Weinberg, Geoffrey A, Staat, Mary A, McNeal, Monica M, Selvarangan, Rangaraj, Halasa, Natasha B, Englund, Janet A, Boom, Julie A, Azimi, Parvin H, Szilagyi, Peter G, Harrison, Christopher J, Williams, John V, Klein, Eileen J, Stewart, Laura S, Sahni, Leila C, Singer, Monica N, Lively, Joana Y, and Payne, Daniel C
- Subjects
- *
INFLUENZA vaccines , *CONFIDENCE intervals , *MULTIPLE regression analysis , *RESPIRATORY infections in children , *INTERVIEWING , *DOCUMENTATION , *SOCIOECONOMIC factors , *DESCRIPTIVE statistics , *HOSPITAL care of children - Abstract
Background Parent-reported influenza vaccination history may be valuable clinically and in influenza vaccine effectiveness (VE) studies. Few studies have assessed the validity of parental report among hospitalized children. Methods Parents of 2597 hospitalized children 6 months–17 years old were interviewed from November 1, 2015 to June 30, 2016, regarding their child's sociodemographic and influenza vaccination history. Parent-reported 2015–2016 influenza vaccination history was compared with documented vaccination records (considered the gold standard for analysis) obtained from medical records, immunization information systems, and providers. Multivariable logistic regression analyses were conducted to determine potential factors associated with discordance between the 2 sources of vaccination history. Using a test-negative design, we estimated VE using vaccination history obtained through parental report and documented records. Results According to parental report, 1718 (66%) children received the 2015–2016 influenza vaccine, and of those, 1432 (83%) had documentation of vaccine receipt. Percent agreement was 87%, with a sensitivity of 96% (95% confidence interval [CI], 95%–97%) and a specificity of 74% (95% CI, 72%–77%). In the multivariable logistic regression, study site and child's age 5–8 years were significant predictors of discordance. Adjusted VE among children who received ≥1 dose of the 2015–2016 influenza vaccine per parental report was 61% (95% CI, 43%–74%), whereas VE using documented records was 55% (95% CI, 33%–69%). Conclusions Parental report of influenza vaccination was sensitive but not as specific compared with documented records. However, VE against influenza-associated hospitalizations using either source of vaccination history did not differ substantially. Parental report is valuable for timely influenza VE studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. NOSOCOMIAL INFECTION WITH ECHOVIRUS TYPE II IN HANDICAPPED AND PREMATURE INFANTS.
- Author
-
Cramblett, Henry G., Haynes, Ralph E., Azimi, Parvin H., Hilty, Milo D., and Wilder, Michael H.
- Subjects
- *
NOSOCOMIAL infections in children , *ECHO viruses , *PREMATURE infants , *CHILDREN with disabilities - Abstract
This report describes an outbreak of nosocomial infections due to echovirus type 11 among premature and/or handicapped infants in an intensive care unit. Four patients became ill within a short period of time and echovirus 11 was recovered from several of their specimens. The illnesses were clinically suggestive of bacterial sepsis and/or bacterial meningitis. Each of the four infants who became ill was in an isolette for a period of from 20 to 54 days before onset of illness. Three of the four patients became ill within 24 hours of one another which suggested a common exposure at nearly the same time. No index case could be identified, but it appears that this outbreak of enteroviral infections was due to inadequate hand washing by personnel. The outbreak was halted by removing the infants to an infectious disease unit and by closing the involved unit to new admissions for seven days. [ABSTRACT FROM AUTHOR]
- Published
- 1973
- Full Text
- View/download PDF
14. Vaccine Effectiveness Against Influenza Hospitalization Among Children in the United States, 2015–2016.
- Author
-
Feldstein, Leora R, Ogokeh, Constance, Rha, Brian, Weinberg, Geoffrey A, Staat, Mary A, Selvarangan, Rangaraj, Halasa, Natasha B, Englund, Janet A, Boom, Julie A, Azimi, Parvin H, Szilagyi, Peter G, McNeal, Monica, Harrison, Christopher J, Williams, John V, Klein, Eileen J, Sahni, Leila C, Singer, Monica N, Lively, Joana Y, Payne, Daniel C, and Fry, Alicia M
- Subjects
- *
INFLUENZA prevention , *INFLUENZA vaccines , *IMMUNIZATION , *CONFIDENCE intervals , *RESPIRATORY infections , *DESCRIPTIVE statistics , *INFLUENZA B virus , *ELECTRONIC health records , *ODDS ratio , *LOGISTIC regression analysis , *HOSPITAL care of children , *ACUTE diseases , *CHILDREN - Abstract
Background Annual United States (US) estimates of influenza vaccine effectiveness (VE) in children typically measure protection against outpatient medically attended influenza illness, with limited data evaluating VE against influenza hospitalizations. We estimated VE for preventing laboratory-confirmed influenza hospitalization among US children. Methods We included children aged 6 months–17 years with acute respiratory illness enrolled in the New Vaccine Surveillance Network during the 2015–2016 influenza season. Documented influenza vaccination status was obtained from state immunization information systems, the electronic medical record, and/or provider records. Midturbinate nasal and throat swabs were tested for influenza using molecular assays. We estimated VE as 100% × (1 – odds ratio), comparing the odds of vaccination among subjects testing influenza positive with subjects testing negative, using multivariable logistic regression. Results Of 1653 participants, 36 of 707 (5%) of those fully vaccinated, 18 of 226 (8%) of those partially vaccinated, and 85 of 720 (12%) of unvaccinated children tested positive for influenza. Of those vaccinated, almost 90% were documented to have received inactivated vaccine. The majority (81%) of influenza cases were in children ≤ 8 years of age. Of the 139 influenza-positive cases, 42% were A(H1N1)pdm09, 42% were B viruses, and 14% were A(H3N2). Overall, adjusted VE for fully vaccinated children was 56% (95% confidence interval [CI], 34%–71%) against any influenza-associated hospitalization, 68% (95% CI, 36%–84%) for A(H1N1)pdm09, and 44% (95% CI, –1% to 69%) for B viruses. Conclusions These findings demonstrate the importance of annual influenza vaccination in prevention of severe influenza disease and of reducing the number of children who remain unvaccinated or partially vaccinated against influenza. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Infectious Causes of Acute Gastroenteritis in US Children Undergoing Allogeneic Hematopoietic Cell Transplant: A Longitudinal, Multicenter Study.
- Author
-
Schuster, Jennifer E, Johnston, Samantha H, Piya, Bhinnata, Dulek, Daniel E, Wikswo, Mary E, McHenry, Rendie, Browne, Hannah, Gautam, Rashi, Bowen, Michael D, Vinjé, Jan, Payne, Daniel C, Azimi, Parvin, Selvarangan, Rangaraj, Halasa, Natasha, and Englund, Janet A
- Subjects
- *
BACTERIAL disease complications , *GASTROENTERITIS , *HEMATOPOIETIC stem cell transplantation , *LONGITUDINAL method , *MEDICAL cooperation , *RESEARCH , *VIRUS diseases , *ACUTE diseases , *DISEASE complications , *ADOLESCENCE , *CHILDREN - Abstract
Background Acute gastroenteritis (AGE) in hematopoietic cell transplant (HCT) patients causes significant morbidity and mortality. Data regarding the longitudinal assessment of infectious pathogens during symptomatic AGE and asymptomatic periods, particularly in children, are limited. We investigated the prevalence of AGE-associated infectious pathogens in children undergoing allogeneic HCT. Methods From March 2015 through May 2016, 31 pediatric patients at 4 US children's hospitals were enrolled and had stool collected weekly from pre-HCT through 100 days post-HCT for infectious AGE pathogens by molecular testing. Demographics, clinical symptoms, antimicrobials, vaccination history, and outcomes were manually abstracted from the medical record into a standardized case report form. Results We identified a pathogen in 18% (38/206) of samples, with many detections occurring during asymptomatic periods. Clostridioides difficile was the most commonly detected pathogen in 39% (15/38) of positive specimens, although only 20% (3/15) of C. difficile –positive specimens were obtained from children with diarrhea. Detection of sapovirus, in 21% (8/38) of pathogen-positive specimens, was commonly associated with AGE, with 87.5% of specimens obtained during symptomatic periods. Norovirus was not detected, and rotavirus was detected infrequently. Prolonged shedding of infectious pathogens was rare. Conclusions This multicenter, prospective, longitudinal study suggests that the epidemiology of AGE pathogens identified from allogeneic HCT patients may be changing. Previously reported viruses, such as rotavirus and norovirus, may be less common due to widespread vaccination and institution of infection control precautions, and emerging viruses such as sapoviruses may be increasingly recognized due to the use of molecular diagnostics. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Evidence for Household Transmission of Rotavirus in the United States, 2011–2016.
- Author
-
Wikswo, Mary E, Parashar, Umesh D, Lopman, Benjamin, Selvarangan, Rangaraj, Harrison, Christopher J, Azimi, Parvin H, Boom, Julie A, Sahni, Leila C, Englund, Janet A, Klein, Eileen J, Staat, Mary Allen, McNeal, Monica M, Halasa, Natasha, Chappell, James, Weinberg, Geoffrey A, Szilagyi, Peter G, Esona, Mathew D, Bowen, Michael D, and Payne, Daniel C
- Subjects
- *
INFECTIOUS disease transmission , *GASTROENTERITIS , *GASTROENTERITIS in children , *PEDIATRICS , *PREVENTIVE health services , *ROTAVIRUSES , *HOME environment , *ROTAVIRUS vaccines , *DESCRIPTIVE statistics , *ODDS ratio - Abstract
Background Rotavirus is a leading cause of acute gastroenteritis (AGE) in children and is highly transmissible. In this study, we assessed the presence of AGE in household contacts (HHCs) of pediatric patients with laboratory-confirmed rotavirus. Methods Between December 2011 and June 2016, children aged 14 days to 11 years with AGE were enrolled at 1 of 7 hospitals or emergency departments as part of the New Vaccine Surveillance Network. Parental interviews, medical and vaccination records, and stool specimens were collected at enrollment. Stool was tested for rotavirus by an enzyme immunoassay and confirmed by real-time or conventional reverse transcription-polymerase chain reaction assay or repeated enzyme immunoassay. Follow-up telephone interviews were conducted to assess AGE in HHCs the week after the enrolled child's illness. A mixed-effects multivariate model was used to calculate odds ratios. Results Overall, 829 rotavirus-positive subjects and 8858 rotavirus-negative subjects were enrolled. Households of rotavirus-positive subjects were more likely to report AGE illness in ≥1 HHC than were rotavirus-negative households (35% vs 20%, respectively; P <.0001). A total of 466 (16%) HHCs of rotavirus-positive subjects reported AGE illness. Of the 466 ill HHCs, 107 (23%) sought healthcare; 6 (6%) of these encounters resulted in hospitalization. HHCs who were <5 years old (odds ratio, 2.2 [ P =.004]) were more likely to report AGE illness than those in other age groups. In addition, 144 households reported out-of-pocket expenses (median, $20; range, $2–$640) necessary to care for an ill HHC. Conclusions Rotavirus-associated AGE in children can lead to significant disease burden in HHCs, especially in children aged <5 years. Prevention of pediatric rotavirus illness, notably through vaccination, can prevent additional illnesses in HHCs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Foreign Body Pulmonary Granulomas in an Abuser of Nasally Inhaled Drugs.
- Author
-
Johnson, Daniel Corey, Petru, Ann, and Azimi, Parvin H.
- Subjects
- *
PNEUMONIA , *AMPHETAMINES , *DRUG abuse , *TALC , *HEALTH , *PHYSIOLOGY - Abstract
Presents a case of foreign body granulomas in the lungs of a teenager who abused methamphetamines by nasal inhalation. Ingredients used to reduce the concentration of street drugs; Symptoms manifested by intravenous drug abusers; Pulmonary diseases resulting from inhaled talc; Signs showing talc aspiration.
- Published
- 1991
- Full Text
- View/download PDF
18. Factors Associated With Rotavirus Vaccine Coverage.
- Author
-
Aliabadi, Negar, Wikswo, Mary E., Tate, Jacqueline E., Cortese, Margaret M., Szilagyi, Peter G., Staat, Mary Allen, Weinberg, Geoffrey A., Halasa, Natasha B., Boom, Julie A., Selvarangan, Rangaraj, Englund, Janet A., Azimi, Parvin H., Klein, Eileen J., Moffatt, Mary E., Harrison, Christopher J., Sahni, Leila C., Stewart, Laura S., Bernstein, David I., Parashar, Umesh D., and Payne, Daniel C.
- Subjects
- *
EDUCATION of mothers , *GASTROENTERITIS , *ACADEMIC medical centers , *BLACK people , *CONFIDENCE intervals , *DPT vaccines , *INCOME , *PREMATURE infants , *MULTIVARIATE analysis , *VACCINATION , *LOGISTIC regression analysis , *TREATMENT duration , *ROTAVIRUS vaccines , *ODDS ratio , *CHILDREN , *PREVENTION - Abstract
BACKGROUND: Rotavirus vaccines (RVVs) were included in the US immunization program in 2006 and are coadministered with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine, yet their coverage lags behind DTaP. We assessed timing, initiation, and completion of the RVV series among children enrolled in active gastroenteritis surveillance at 7 US medical institutions during 2014-2016. METHODS: We compared coverage and timing of each vaccine series and analyzed characteristics associated with RVV initiation and completion. We report odds ratios (ORs) and 95% confidence intervals (CIs) from multivariable logistic regression models. RESULTS: We enrolled 10 603 children. In 2015, $1 dose coverage was 91% for RVV and 97% for DTaP. Seven percent of children received their first DTaP vaccine at age $15 weeks versus 4% for RVV (P # .001). Recent birth years (2013-2016) were associated with higher odds of RVV initiation (OR = 5.72; 95% CI 4.43-7.39), whereas preterm birth (OR = 0.32; 95% CI 0.24-0.41), older age at DTaP initiation (OR 0.85; 95% CI 0.80-0.91), income between $50 000 and $100 000 (OR = 0.56; 95% CI 0.40-0.78), and higher maternal education (OR = 0.52; 95% CI 0.36-0.74) were associated with lower odds. Once RVV was initiated, recent birth years (2013-2016; OR = 1.57 [95% CI 1.32-1.88]) and higher maternal education (OR = 1.31; 95% CI 1.07-1.60) were associated with higher odds of RVV completion, whereas preterm birth (OR = 0.76; 95% CI 0.62-0.94), African American race (OR = 0.82; 95% CI 0.70-0.97) and public or no insurance (OR = 0.75; 95% CI 0.60-0.93) were associated with lower odds. Regional differences existed. CONCLUSIONS: RVV coverage remains lower than that for the DTaP vaccine. Timely DTaP administration may help improve RVV coverage. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Intestinal Carriage of Third-Generation Cephalosporin-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Healthy US Children.
- Author
-
Islam, Shamim, Selvarangan, Rangaraj, Kanwar, Neena, McHenry, Rendie, Chappell, James D, Halasa, Natasha, Wikswo, Mary E, Payne, Daniel C, Azimi, Parvin H, and McDonald, L Clifford
- Subjects
- *
INTESTINAL diseases , *CEPHALOSPORIN analysis , *ANTIBIOTICS , *DRUG resistance in microorganisms , *ENTEROBACTERIACEAE , *ESCHERICHIA coli , *HOSPITAL care , *HOST-bacteria relationships , *HYDROLASES , *KLEBSIELLA , *MEDICAL appointments , *MICROBIAL sensitivity tests , *MULTIDRUG resistance , *SURVEYS , *PHENOTYPES , *CHILDREN , *DISEASE risk factors - Abstract
Background The epidemiology of antibiotic-resistant Enterobacteriaceae intestinal carriage in healthy US children has not been well characterized. Methods Children between 14 days and 14 years of age were enrolled during well-child visits in Oakland, California, Kansas City, Kansas, and Nashville, Tennessee, between December 2013 and March 2015. Data on recent antibiotic use by the child and travel and hospitalization history of all members of each child’s household were obtained with a risk-factor survey. Stool specimens collected from the subjects were screened for extended-spectrum β-lactamase-producing (ESBL-P) bacteria using CHROMagar ESBL medium. Putative ESBL-P Escherichia coli and Klebsiella colonies underwent phenotypic confirmation by double-disk synergy testing; confirmed third-generation cephalosporin-resistant (3GCR) isolates underwent additional antibiotic-susceptibility testing. Results In 519 subjects, the overall 3GCR Enterobacteriaceae carriage rate was 4.4% (n = 23) and ranged from 3.4% to 5.1% among the study sites. The ESBL-P Enterobacteriaceae carriage rate was 3.5% (n = 18). The rates of 3GCR Enterobacteriaceae carriage was highest in 1 to <2 year olds at 6.5%, and was 5.2% in <5 year-olds vs 1.7% in ≥5-year-olds (P =.11). 3GCR and ESBL-P Enterobacteriaceae carriage was associated with international travel within the previous year; 11.1% of ESBL-P Enterobacteriaceae carriers reported this history compared with 1.6% of noncarriers (P =.004). No other queried factor was found to increase risk. Of the 24 analyzed 3GCR isolates, 58% were multidrug resistant. Conclusions The 3GCR Enterobacteriaceae carriage rate exceeds 5% in healthy US children <5 years of age. International travel within the previous year increased the risk of 3GCR and ESBL-P Enterobacteriaceae carriage. In contrast, we found no differences in the rates of hospitalization or recent antibiotic exposure between carriers and noncarriers. Young children, who have the highest prevalence of colonization, might be a sentinel population to study to gain a better understanding of community sources of antibiotic-resistant Enterobacteriaceae. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008-2013.
- Author
-
Bowen, Michael D., Mijatovic-Rustempasic, Slavica, Esona, Mathew D., Teel, Elizabeth N., Gautam, Rashi, Sturgeon, Michele, Azimi, Parvin H., Baker, Carol J., Bernstein, David I., Boom, Julie A., Chappell, James, Donauer, Stephanie, Edwards, Kathryn M., Englund, Janet A., Halasa, Natasha B., Harrison, Christopher J., Johnston, Samantha H., Klein, Eileen J., McNeal, Monica M., and Moffatt, Mary E.
- Subjects
- *
ROTAVIRUSES , *GASTROENTERITIS , *GENOTYPES , *ENZYME-linked immunosorbent assay , *DISEASE prevalence - Abstract
Background: Group A rotaviruses (RVA) are a significant cause of pediatric gastroenteritis worldwide. The New Vaccine Surveillance Network (NVSN) has conducted active surveillance for RVA at pediatric hospitals and emergency departments at 3-7 geographically diverse sites in the United States since 2006.Methods: Over 6 consecutive years, from 2008 to 2013, 1523 samples from NVSN sites that were tested positive by a Rotaclone enzyme immunoassay were submitted to the Centers for Disease Control and Prevention for genotyping.Results: In the 2009, 2010, and 2011 seasons, genotype G3P[8] was the predominant genotype throughout the network, with a 46%-84% prevalence. In the 2012 season, G12P[8] replaced G3P[8] as the most common genotype, with a 70% prevalence, and this trend persisted in 2013 (68.0% prevalence). Vaccine (RotaTeq; Rotarix) strains were detected in 0.6%-3.4% of genotyped samples each season. Uncommon and unusual strains (eg, G8P[4], G3P[24], G2P[8], G3P[4], G3P[6], G24P[14], G4P[6], and G9P[4]) were detected sporadically over the study period. Year, study site, and race were found to be significant predictors of genotype.Conclusions: Continued active surveillance is needed to monitor RVA genotypes in the United States and to detect potential changes since vaccine licensure. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
21. Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009–2011.
- Author
-
Payne, Daniel C., Boom, Julie A., Staat, Mary Allen, Edwards, Kathryn M., Szilagyi, Peter G., Klein, Eileen J., Selvarangan, Rangaraj, Azimi, Parvin H., Harrison, Christopher, Moffatt, Mary, Johnston, Samantha H., Sahni, Leila C., Baker, Carol J., Rench, Marcia A., Donauer, Stephanie, McNeal, Monica, Chappell, James, Weinberg, Geoffrey A., Tasslimi, Azadeh, and Tate, Jacqueline E.
- Subjects
- *
ROTAVIRUS vaccines , *DRUG efficacy , *GASTROENTERITIS in children , *PUBLIC health surveillance , *HEALTH risk assessment , *AMERICAN children , *HEALTH , *VACCINATION - Abstract
Using a large, pediatric active surveillance network throughout the United States, both licensed and concurrently used rotavirus vaccines significantly protected against medically attended rotavirus gastroenteritis. Vaccine performance appeared to neither diminish over time, nor differ by predominant circulating rotavirus strain, including G12P[8].Background We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in US children.Methods We enrolled children <5 years of age hospitalized or visiting the ED with AGE symptoms from November 2009–June 2010 and from November 2010–June 2011 at 7 medical institutions. Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped. Vaccination among laboratory-confirmed rotavirus cases was compared with rotavirus-negative AGE controls. Regression models calculated VE estimates for each vaccine, age, ethnicity, genotype, and clinical setting.Results RV5-specific analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE controls. RV5 and RV1 were 84% (95% confidence interval [CI], 78%–88%) and 70% (95% CI, 39%–86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 81% (95% CI, 70%–84%) and 86% (95% CI, 74%–91%), respectively. RV1 was 78% (95% CI, 46%–91%) effective against ED rotavirus disease; study power was insufficient to evaluate inpatient RV1 VE. No waning of immunity was evident during the first 4 years of life for RV5, nor during the first 2 years of life for RV1. RV5 provided genotype-specific protection against each of the predominant strains (G1P[8], G2P[4], G3P[8], G12P[8]), while RV1 VE was statistically significant for the most common genotype, G3P[8].Conclusions Both RV5 and RV1 significantly protected against medically attended rotavirus gastroenteritis in this real-world assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. Quantitation of human astrovirus by real-time reverse-transcription-polymerase chain reaction to examine correlation with clinical illness
- Author
-
Zhang, Zhian, Mitchell, Douglas K., Afflerbach, Carol, Jakab, Ferenc, Walter, Jolan, Zhang, Yan-Jin, Staat, Mary A., Azimi, Parvin, and Matson, David O.
- Subjects
- *
VIRUS diseases , *POLYMERASE chain reaction , *MOLECULAR genetics , *GASTROINTESTINAL diseases - Abstract
Abstract: Human astroviruses (HAstVs) cause gastroenteritis. Real-time, reverse-transcription-polymerase chain reaction (RT2-PCR) was developed to quantitate HAstV RNA. An 88bp amplicon from the conserved 3′ genomic region was detected by binding of SYBR Green. RT2-PCR was reproducible, with a correlation coefficient of 0.998–1.00 and PCR efficiency of 94.4–100% (mean 97%). The coefficient of variation was 0.6–2.5%, dynamic range with RNA standard up to 5×108 RNA copies (RNACN) and sensitivity 5 RNACN. Of 54 blinded, archived stool samples from children hospitalized because of gastroenteritis tested by RT-PCR, 49 (91%) agreed by RT2-PCR for HAstV-positivity (Cohen κ =0.81, 95%CI 0.66–0.97). HAstV RNACN in stools ranged from 7.6×101 to 3.6×1014 copies/0.1g. Children coinfected with rotavirus had lower RNACN (mean log 4.22/standard deviation=2.26) than those without coinfection (7.57/3.06; p =.019). Children taking infant formula also had lower RNACN (5.96/2.98) than breast-fed or weaned children (8.73/2.92; p =.027). Higher RNACN tended to occur with longer duration of diarrhea for the episode (r =0.49, p =.064), but was not associated with change in age, gender, illness day, severity or breast-feeding. RT2-PCR quantitated HAstV RNA and RNACN in stool correlates with features of clinical illness. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
23. 2639. Respiratory Virus Detections in Asthma-Related Pediatric Hospitalizations: New Vaccine Surveillance Network, United States.
- Author
-
Midgley, Claire, Rha, Brian, Lively, Joana Y, Campbell, Angela P, Boom, Julie A, Azimi, Parvin H, Weinberg, Geoffrey A, Staat, Mary A, Halasa, Natasha B, Selvarangan, Rangaraj, Englund, Janet A, Klein, Eileen J, Harrison, Christopher J, Williams, John V, Schlaudecker, Elizabeth P, Szilagyi, Peter G, Singer, Monica Nayakwadi, Sahni, Leila C, Curns, Aaron, and Payne, Daniel C
- Subjects
- *
RESPIRATORY syncytial virus , *HUMAN metapneumovirus infection , *PARAINFLUENZA viruses , *RNA virus infections , *VIRUSES , *RESPIRATORY infections - Abstract
Background Respiratory viruses are associated with most asthma exacerbations (AEx) in children; however, the role of different viruses in AEx is unclear. We describe respiratory virus detections among pediatric inpatients with AEx (AEx-inpatients). Methods Through active, prospective surveillance at 7 US medical centers, we enrolled inpatients (<18 years) with acute respiratory illness (ARI) during November 1, 2015–June 30, 2016. We defined an AEx-inpatient as an inpatient with a principal admission or discharge diagnosis of asthma (ICD-10-CM, J45.xx). Mid-turbinate nasal and/or throat swabs were tested by molecular assays for influenza A or B, respiratory syncytial virus (RSV), parainfluenza virus 1–3, rhinovirus or enterovirus (RV/EV), human metapneumovirus and adenovirus. We assessed virus detections among AEx-inpatients throughout the surveillance period or by season (winter: December–February; spring: March–May), and by patient age and history of asthma/reactive airway disease (asthma/RAD). Results We tested 3,897 inpatients with ARI; of whom, 954 were AEx-inpatients. Most AEx-inpatients (741/954 [78%]) reported an asthma/RAD history. Viruses were more frequently detected among AEx-inpatients <5 years (350/458 [76%]) than 5–17 years (305/496 [61%], P < 0.001). Most (615/655 [94%]) detections were of single viruses. The most frequent single virus detections were RV/EV (474/954 [50%]) and RSV (76/954 [8%]) but the frequency of each virus varied by season and age group (figure). Single RV/EVs were the most common virus detections in both seasons and all groups. Single RSV detections were prominent among <5 year olds in winter (40/185 [22%]). Among those with single RV/EV or RSV detections, 285/474 (60%) and 49/76 (64%) required supplemental oxygen, respectively (P = 0.676); median length of stay was 1 day (range: 0–45; IQR: 1–2) and 2 days (range: 0–6; IQR: 1–2.5), respectively (P < 0.001). Conclusion AEx-inpatients <5 years were more likely to have respiratory virus detections than those 5–17 years. Single RV/EVs formed the majority of virus detections throughout the surveillance period, regardless of age. RSV played a notable role in winter among patients <5 years. These findings could inform prevention or treatment strategies for virus-associated AEx. Disclosures All authors: No reported disclosures. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. 2328. Human Respiratory Syncytial Virus Subgroups among Hospitalized Infants in the United States, 2015–2016.
- Author
-
Rha, Brian, Peret, Teresa C T, Wang, Lijuan, Lively, Joana Y, Curns, Aaron, Campbell, Angela P, Boom, Julie A, Azimi, Parvin H, Weinberg, Geoffrey A, Staat, Mary A, Selvarangan, Rangaraj, Halasa, Natasha B, Englund, Janet A, Klein, Eileen J, Harrison, Christopher J, Stewart, Laura S, Szilagyi, Peter G, Singer, Monica Nayakwadi., Avadhanula, Vasanthi, and McNeal, Monica
- Subjects
- *
RESPIRATORY syncytial virus , *REVERSE transcriptase polymerase chain reaction , *INFANTS , *RESPIRATORY syncytial virus infections , *DISEASE susceptibility - Abstract
Background Respiratory syncytial virus (RSV) is a major cause of severe acute respiratory illnesses (ARI) in young children. Circulation of RSV subgroups A and B can vary by season and geographic location, and may have implications for disease susceptibility, outcomes, and prevention measures. We investigated RSV subgroup distribution among samples collected in the New Vaccine Surveillance Network. Methods Prospective active surveillance for hospitalized ARI was conducted from November 1, 2015 to June 30, 2016 among children < 12 months of age at seven pediatric hospital sites. Mid-turbinate nasal and throat flocked swabs (combined when both available) and/or tracheal aspirates were collected and tested for RSV at each site using real-time reverse transcription polymerase chain reaction (rRT–PCR) assays; RSV A/B subgroup results were available from four sites that did their own subgroup testing (Cincinnati, Kansas City, Houston, and Oakland). At three sites (Rochester, Nashville, Seattle), approximately 50 RSV-positive specimens were sampled based on the monthly distribution for each site and 1:1 distribution by gender, and then assayed for subgroup at CDC. Patient information was obtained from medical records; chi-square tests were used to compare the distribution of A and B subgroups by site. Results Of 704 RSV-positive hospitalized infants, subgroup data from 586 were analyzed; 340 (58%) were RSV A and 246 (42%) were RSV B. The median age for both RSV A and RSV B patients was 2 months. Subgroup distribution varied by geographic location, with the overall proportion of RSV A ranging from 18–83% across sites (P < 0.01). Peak RSV A and B detections by month varied by site, occurring from November–February (figure). Conclusion During the 2015–2016 season, RSV A and B subgroups co-circulated among hospitalized infants enrolled at seven US sites. The predominance of RSV subgroup varied by geographic location. Continued surveillance and additional subgroup testing over multiple seasons should improve understanding of the epidemiologic significance of RSV infections by subgroup. Disclosures All authors: No reported disclosures. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Prevalence and genetic characterization of caliciviruses among children hospitalized for acute gastroenteritis in the United States
- Author
-
Zintz, Carmelann, Bok, Karin, Parada, Ester, Barnes-Eley, Myra, Berke, Tamas, Staat, Mary A., Azimi, Parvin, Jiang, Xi, and Matson, David O.
- Subjects
- *
CALICIVIRUSES , *RNA viruses , *GASTROENTERITIS , *GASTROINTESTINAL diseases , *GENETICS - Abstract
Abstract: Human calicivirus was the first recognized viral agent causing gastroenteritis in humans. Norovirus (NV) and Sapovirus (SV), two genera within the Caliciviridae family, cause epidemic and endemic acute gastroenteritis in children and adults. The role of these viruses as a cause of sporadic acute gastroenteritis in young children requiring hospitalization is not well established. The aim of this study was to assess the prevalence and genetic diversity of caliciviruses among children hospitalized with symptoms of acute gastroenteritis. Stool samples were collected over 2 years from symptomatic children (N =1840) up to 5 years of age at three pediatric hospitals in the US. Overall, 156 (8.5%) samples were CV-positive, 131 (7.1%) confirmed by sequencing to be NV and 25 (1.4%) confirmed to be SV. Sequences of RT-PCR-amplified polymerase gene segments were analyzed using distance, maximum likelihood and parsimony algorithms. Phylogenetic analysis of 97 NV sequences showed that seven strains were in genogroup I, 86 strains were in genogroup II and four strains were not in genogroup I, II, or III, likely representing three new NV genogroups IV, VI and VII. Genogroup I and genogroup II strains were in 12 new genetic clusters, three in genogroup I and nine in genogroup II. Within genogroups I and II, most (98%) NV strains were in genetic clusters with no known prototype in GenBank. Phylogenetic analysis of 24 SV strains showed that half grouped with the London/92 strain in one genogroup and the remainder in three other proposed genogroups, one novel. In conclusion, NV and SV were frequent causes of hospitalization for acute gastroenteritis in young children and infecting strains were highly diverse, including newly recognized genogroups and genetic clusters within known genogroups. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
26. Rotavirus antigenemia in children is associated with viremia.
- Author
-
Blutt, Sarah E., Matson, David O., Crawford, Sue E., Staat, Mary Allen, Azimi, Parvin, Bennett, Berkeley L., Piedra, Pedro A., and Conner, Margaret E.
- Subjects
- *
ROTAVIRUS diseases , *DIARRHEA in children , *INTESTINAL diseases , *FECES examination , *CONSTIPATION , *COMPARATIVE studies , *DIARRHEA , *GASTROENTERITIS , *IMMUNOASSAY , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RETROVIRUS diseases , *VIRAL antibodies , *VIRAL antigens , *ROTAVIRUSES , *EVALUATION research , *VIREMIA , *DIAGNOSIS - Abstract
Background: Antigenemia is commonly detected in rotavirus-infected children. Although rotavirus RNA has been detected in serum, definitive proof of rotavirus viremia has not been shown. We aimed to analyze a defined patient population to determine if infectious virus could be detected in sera from children with rotavirus antigenemia.Methods and Findings: Serum samples obtained upon hospitalization from children with gastroenteritis (57 stool rotavirus-positive and 41 rotavirus-negative), children with diagnosed bronchiolitis of known (n = 58) or unknown (n = 17) viral etiology, children with noninfectious, nonchronic conditions (n = 17), and healthy adults (n = 28) were tested for rotavirus antigen by enzyme immunoassay (EIA). Results of serum antigen testing were assessed for association with clinical and immunological attributes of the children. Rotavirus antigenemia was detected in 90% (51/57) of children with rotavirus-positive stools, in 89% (8/9) of children without diarrhea but with rotavirus-positive stools, in 12% (2/17) of children with bronchiolitis of unknown etiology without gastroenteritis, and in 12% (5/41) of children with gastroenteritis but with rotavirus-negative stools. Antigenemia was not detected in sera from children with noninfectious nonchronic conditions, children with bronchiolitis of known etiology and no gastroenteritis, or healthy adults. Neither age nor timing of serum collection within eight days after onset of gastroenteritis significantly affected levels of antigenemia, and there was no correlation between antigenemia and viral genotype. However, there was a negative correlation between serum rotavirus antigen and acute rotavirus-specific serum IgA (r = -0.44, p = 0.025) and IgG (r = -0.40, p = 0.01) titers. We examined 11 antigen-positive and nine antigen-negative sera for infectious virus after three blind serial passages in HT-29 cells using immunofluorescence staining for rotavirus structural and nonstructural proteins. Infectious virus was detected in 11/11 (100%) sera from serum antigen-positive children and in two out of nine (22%) sera samples from antigen-negative children (p = 0.002).Conclusions: Most children infected with rotavirus are viremic. The presence of viremia is directly related to the detection of antigenemia and is independent of the presence of diarrhea. Antigenemia load is inversely related to the titer of antirotavirus antibody in the serum. The finding of infectious rotavirus in the blood suggests extraintestinal involvement in rotavirus pathogenesis; however, the impact of rotavirus viremia on clinical manifestations of infection is unknown. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.